SAN DIEGO, Nov. 04, 2015 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age‐related macular degeneration (AMD) and fibrotic diseases, today announced that the Company will host a Key Opinion Leader breakfast for investors, focused on current advances in sarcoma treatment. The discussions will include an overview of TRC105, TRACON’s novel, clinical stage antibody to endoglin. The event and live webcast will take place on Friday, November 13, from 8:00am to 9:30am Eastern Time in New York City.
The meeting will feature keynote presentations by key opinion leaders, Steven Attia, D.O., a medical oncologist and research chair of the Mayo Clinic Sarcoma Research Disease Oriented Group at the Mayo Clinic in Jacksonville, Florida, and Robert Maki, M.D., Ph.D., a professor of Medicine, Pediatrics and Orthopaedics, and the Steven Ravitch Chair in Pediatric Hematology-Oncology at Mount Sinai Hospital. The TRACON management team will also provide an overview of the Company's operations and ongoing clinical development work with TRC105 in soft tissue sarcoma, which is currently in a Phase 2 clinical trial in combination with Votrient® (pazopanib), a vascular endothelial growth factor (VEGF) inhibitor, to treat patients with soft tissue sarcoma. A Q&A session with the featured experts and management will follow the presentations.
The event is intended for institutional investors and sell-side analysts only. To reserve a place, please contact Mac MacDonald at 212-915-2567, or via e-mail at email@example.com. A live webcast and subsequent replay of the event will also be available to the public in the “Events and Presentation” section within the “Investors” section of the TRACON Pharmaceuticals website at www.traconpharma.com.
About the Key Opinion Leader Participants
Dr. Attia is a medical oncologist at the Mayo Clinic in Jacksonville, Florida, where he serves as the research chair of the Mayo Clinic Sarcoma Research Disease Oriented Group. Dr. Attia’s clinical and research focus is patients with desmoid tumors, sarcomas of soft tissue and bone, including angiosarcoma and gastrointestinal stromal tumor (GIST), as well as epithelioid hemangioendothelioma (EHE), chordoma and other locally aggressive or malignant tumors of soft tissue and bone. Aside from clinical trials and patient care, Dr. Attia has an interest in optimizing the way patients with rare tumors are discussed. He chairs a first-in-kind, CME-accredited, weekly international sarcoma tumor board that he founded in 2010, which connects ten sarcoma centers in the U.S. and Europe to review challenging cases at these centers. Dr. Attia completed his fellowship at the University of Wisconsin.
Dr. Maki is a professor of Medicine, Pediatrics and Orthopaedics, and the Steven Ravitch Chair in Pediatric Hematology-Oncology at Mount Sinai Hospital. He has published more than 100 articles on sarcoma treatment and basic science research, having worked on studies related to sarcoma since 1985. Dr. Maki treats adults and children with sarcomas and has an interest in translational research and the biology that leads to different types of sarcomas. Dr. Maki’s efforts at Mount Sinai are directed towards an increasingly integrative effort in sarcoma biology and the treatment of sarcomas. His group conducts clinical trials in adults with sarcomas, as well as translational studies in sarcoma biology, to identify the next possible targets for new drugs to treat these cancers.
TRC105 is a novel, clinical stage antibody to endoglin, a protein overexpressed on proliferating endothelial cells that is essential for angiogenesis, the process of new blood vessel formation. TRC105 is currently being studied in multiple Phase 2 clinical trials sponsored by both TRACON and the National Cancer Institute for the treatment of multiple solid tumor types in combination with VEGF inhibitors. TRC105 is also being developed in combination with VEGF inhibitor treatments in wet AMD. For more information about the clinical trials, please visit TRACON’s website at http://www.traconpharma.com/clinical_trials.php.
TRACON develops targeted therapies for cancer, ophthalmic and fibrotic diseases. TRACON’s pipeline includes two clinical stage product candidates: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers and wet AMD through a collaboration with Santen Pharmaceutical Company Ltd., and TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com.
Source:TRACON Pharmaceuticals, Inc.